Hyperandrogenism, Elevated 17-Hydroxyprogesterone and Its Urinary Metabolites in a Young Woman with Ovarian Steroid Cell Tumor, Not Otherwise Specified: Case Report and Review of the Literature

Table 1

Pre- and postoperative laboratory results.

Tests (serum/plasma)	Concentration (before operation)	Concentration (2 weeks after operation)	Concentration (4 weeks after operation)	Reference interval
Luteinizing hormone (IU/L)	10.0	4.5	—	2.4–12.6 (follicular phase)
				14.0–95.6 (ovulation phase)
				1.0–11.4 (luteal phase)
Follicle-stimulating hormone (IU/L)	5.0	4.0	—	3.5–12.5 (follicular phase)
				4.7–21.5 (ovulation phase)
				1.7–7.7 (luteal phase)
Estradiol (pmol/L)	161	302	—	98–571 (follicular phase)
				177–1153 (ovulation phase)
				122–1094 (luteal phase)
Progesterone (nmol/L)	—	18.7	—	0.6–4.7 (follicular phase)
				2.4–9.4 (ovulation phase)
				5.3–86 (luteal phase)
Testosterone (nmol/L)	10.6	0.7	0.5	<1.7
Prolactin (mIU/L)	See footnote^a	See footnote^a	—	<496
Androstenedione (nmol/L)	28.2	4.2	3.0	1.1–6.5
DHEA-S^b (µmol/L)	6.0	6.7	5.9	1.0–11.7
17-OHP (nmol/L)	52	4.3	0.7	0.6–4.0 (follicular phase)
				1.0–6.0 (luteal phase)
Cortisol (1 mg overnight dexamethasone suppression test) (nmol/L)	21	—	—	<50
Fasting glucose (mmol/L)	7.2^c	6.0	6.5	≥7.0: Diabetes mellitus
HbA1c (%)	6.9^c	—	—	≥6.5%: Diabetes mellitus
CA125 (kU/L)	17	—	—	<35
Alpha-fetoprotein (µg/L)	8	—	—	<9
Human chorionic gonadotropin (IU/L)	<1	—	—	<1 (premenopausal non pregnant)

^aMacroprolactin present, value within reference limits after PEG precipitation. ^bDHEAS: dehydroepiandrosterone-sulphate. ^cResults obtained at diagnosis, before initiation of anti-diabetic medication.